We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In a recent decision Celgene Inc. v. Canada (Minister of Health) the Federal Court of Canada declared that a drug containing a previously approved medicinal ingredient is nevertheless subject to data protection
